1. In Vivo
  2. >>Leadership

Medtech Investors Gain When The Compass Points To Patients

 
• By Ashley Yeo

Seasoned business developer and investor Oern Stuge has worked with the very biggest in medtech in a career spanning over three decades. He bemoans the harm that European policymakers are doing to the one-time capital of the world of medtech innovation. But on the other hand, he knows that the best ideas have a habit of succeeding, regardless of geography.

alamy

Oern Stuge is a player in and champion of the European medtech ecosystem. He has built a successful and varied career, including at Abbott Laboratories Ltd and Medtronic plc, by identifying innovations and developing opportunities that enhance patient care. He has carried those skills forward into his own company, Orsco Life Sciences AG, which is a platform for investment and a networking vehicle for other stakeholders that have value to add and solutions to bring to the table.

There is a lot of money available to be invested in good targets in health care and the life sciences space, he told In Vivo. The opportunities are plentiful, but the Norwegian, a trained physician with an MD from the University of Oslo, is not as happy as he could be

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from In Vivo

Plans For London Cancer Hub Promises New Destination For Biotech Innovation

 
• By Jo Shorthouse

Plans have been submitted for a £1bn development in London that can home biotech companies and encourages cross collaboration with the Institute of Cancer Research. In Vivo took an exclusive tour of the UK’s prospective new cancer innovation district.

Califf In Conversation: “Decimated” FDA Teams Endanger Biologics Progress

 
• By Barnaby Pickering

In Vivo spoke to the previous commissioner of the US FDA about recent ongoings at the agency, and where he believes policy should be directed for patient and industry benefit.

Rising Leaders 2025: Rob Barrow On Leading MindMed’s Psychedelic Renaissance

 
• By Jo Shorthouse

Rob Barrow's unconventional journey from finance to leading MindMed highlights his innovative approach to psychedelic medicine, aiming to transform mental health treatment with groundbreaking therapies.